Merck: EU approves urothelial carcinoma treatment
(CercleFinance.com) - Merck has announced that the European Commission has approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.
This approval follows the recommendations of the European Oncology and Urology Societies, and is based on positive results from a Phase 3 trial.
This treatment showed significant improvements in overall survival and progression-free survival compared with platinum-based chemotherapy.
Keytruda is now approved in all 27 EU member states, as well as in Iceland, Liechtenstein, Norway and Northern Ireland.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This approval follows the recommendations of the European Oncology and Urology Societies, and is based on positive results from a Phase 3 trial.
This treatment showed significant improvements in overall survival and progression-free survival compared with platinum-based chemotherapy.
Keytruda is now approved in all 27 EU member states, as well as in Iceland, Liechtenstein, Norway and Northern Ireland.
Copyright (c) 2024 CercleFinance.com. All rights reserved.